Medical/Pharmaceuticals APAC News & Press Release Distribution

Zymo Research Unveils PureRec DSN: The Most Selective Duplex-Specific Nuclease

IRVINE, Calif., June 4, 2024 /PRNewswire/ -- Zymo Research, a leader in biotechnological advancement has launched a new nuclease calledPureRec Duplex-Specific Nuclease (DSN) that selectively digests double stranded DNA (dsDNA). This new PureRec DSN promises unparalleled specificity in targeting ...

2024-06-04 21:00 1312

Masdar City to Showcase Its Life Sciences Hub at BIO24 in San Diego

Masdar City to showcase why they are the leading destination for the life sciences sector at BIO24 ABU DHABI, UAE, June 4, 2024 /PRNewswire/ -- Highlighting its growing status as a leading destination for the life sciences sector, Masdar City,Abu Dhabi's flagship sustainable city in theUnited Ar...

2024-06-04 19:57 3503

Masdar City to Showcase Its Life Sciences Hub at BIO24 in San Diego

Fosun International Garners Four Awards from Corporate Governance Asia

Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International winAsia's Best CEO from Corporate Governance Asia Fosun International receives Sustainable Asia Award and Best Corporate Communications Award HONG KONG, June 4, 2024 /PRNewswire/ -- On 31 May 2024, the magazine C...

2024-06-04 18:20 3180

AmpleLogic Launches Advanced aPaaS for Life Sciences with 14 Ready-to-Use Applications

HYDERABAD, India, June 4, 2024 /PRNewswire/ -- AmpleLogic, a leading provider of GAMP solutions, announces the launch of its revolutionaryApplication Platform as a Service (aPaaS) designed specifically for the life sciences sector. This ...

2024-06-04 13:30 1232

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center Phase I/II study evaluating RC8...

2024-06-04 09:38 1568

Waters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer

News Summary: * Waters Xevo™ MRT Mass Spectrometer employs next-generation multi-reflecting time-of-flight technology to deliver class-leading combination of high resolution and speed without compromising analytical performance.i * Delivers up to 6x resolution at maximum speed and up to 2x ma...

2024-06-04 08:00 1453

Waters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer

Optimi Health Awarded Drug Establishment Licence From Health Canada

VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a leading Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to ...

2024-06-03 23:49 1050

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

ADELAIDE, South Australia, June 3, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx's Recombination Based Plasmid System (RBPS) technology with BioCina's CDMO clients....

2024-06-03 23:37 2405

HistoIndex to Showcase Groundbreaking AI-powered Stain-free Digital Pathology Advances with 8 Accepted Abstracts at EASL Congress 2024

* Company to deliver two oral and six poster presentations, including one TOP poster and one selected for poster tour, further reinforcing its leadership position in MASH digital pathology. * HistoIndex's AI-driven solutions provide unprecedented insights into the direct prediction of patient...

2024-06-03 20:00 1973

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

* Results from the phase I part of JSKN003-102 was reported at this ASCO Annual Meeting. * JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dose ...

2024-06-03 10:17 1755

Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and ot...

2024-06-03 09:44 2247

Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-06-03 09:35 2770

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) tothe United States (U.S.) Food and Drug Administration (FDA) for its investigational radi...

2024-06-03 09:08 1559

DB HiTek Advances Global Shutter and SPAD

* Expanding specialized image sensor business applied to machine vision, autonomous vehicles, robotics, and medical devices * Collaborating on product development with leading companies in the US, Japan , andChina by providing global leading-edge processes SEOUL, South Korea, June 3, 2024 /PRN...

2024-06-03 08:00 1833

Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2024-06-02 13:19 4036

CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC

* EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab in combination with chemotherapy as a first-line treatment for non-small cell lung cancer (NSC...

2024-06-02 08:24 3176

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...

2024-06-02 08:00 3047

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...

2024-06-02 08:00 4943

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...

2024-06-02 08:00 3635

Vieworks Showcases Innovative X-ray Imaging Solutions at WCNDT (World Conference on Non-Destructive Testing) 2024

ANYANG, South Korea, May 31, 2024 /PRNewswire/ -- Vieworks, a leading innovator in x-ray imaging solution, recently marked a significant milestone by participating in the 21st World Conference on Non-Destructive Testing (WCNDT) for the first time. Held in Songdo,South Korea, WCNDT 2024 served as ...

2024-05-31 15:44 2011